orenzo Guglielmetti join Ari Colosio, deputy editor of The Lancet Respiratory Medicine, to discuss the ENDTB-Q trial to evaluate the efficacy and safety of a drug regiment to treat TB in individuals with pre-extensively drug-resistant tuberculosis.

Read the full article:

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00194-8/fulltext?dgcid=buzzsprout_icw_podcast_July_25_lanres

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

1d:T47c,Deputy editor Ari Colosio speaks with Dr. Laura Garriga-Grimau of the Val d’Hebron Hospital, Autonomous University of Barcelona. Dr. Garriga-Grimau discusses the first multi-country cohort study to describe the clinical features and standards of care for children and young people with bronchiectasis, drawing on data from the International Pediatric Bronchiectasis Registry.Together, they examine key findings on regional differences in diagnosis, co-morbidities, clinical severity, and treatment practices across eight countries. Dr. Garriga-Grimau highlights the significant burden of bronchiectasis on patients and health systems, as well as the urgent need for earlier diagnosis, harmonised international guidelines, and more equitable research and care.Read the full article:https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00089-X/abstract?dgcid=buzzsprout_icw_podcast_July_25_lanresContinue this conversation on

Carole Mitnick & Lorenzo Guglielmetti on...